The FLOW trial (NEJM 2024) showed semaglutide reduced major kidney events 24% in adults with type 2 diabetes and chronic kidney disease. Stopped early for efficacy. This positions semaglutide alongside SGLT2 inhibitors as a renoprotective agent in T2D + CKD — and raises questions about effects in CKD without diabetes.

The FLOW trial

FLOW enrolled 3,533 adults with T2D and stage 2–4 CKD (eGFR 25–75 mL/min/1.73m² with elevated albuminuria). Randomized to semaglutide 1.0 mg weekly or placebo, on top of standard renoprotective therapy (ACE inhibitor or ARB).

EndpointSemaglutidePlaceboEffect
Composite kidney endpoint(reduced)(higher)HR 0.76 (24% reduction)
Persistent ≥50% eGFR decline(reduced)(higher)HR 0.74
Kidney failure (KRT or sustained eGFR <15)(reduced)(higher)HR 0.80
Kidney or CV death(reduced)(higher)HR 0.71
All-cause mortality(reduced)(higher)HR 0.80

Trial stopped early for efficacy. Trial duration median 3.4 years.

Mechanism in CKD

Beyond glycemic and weight effects, GLP-1 receptor agonists appear to have direct renoprotective effects. Proposed mechanisms include reduced glomerular hyperfiltration, reduced oxidative stress, anti-inflammatory effects on the renal interstitium, and blood pressure reduction. The benefit appears additive to ACE/ARB therapy and likely complementary to SGLT2 inhibitor benefit.

Practical implications

What about CKD without diabetes?

FLOW was T2D-only. The FLOW-NoDM trial program (in CKD without T2D) is enrolling. Mechanism would suggest benefit; trial evidence is forthcoming. SELECT showed mortality and CV benefit in obesity without diabetes; FLOW-NoDM extends that question to kidney endpoints.

Compounded semaglutide for renoprotection?

For patients with T2D + CKD already on insurance-covered Ozempic, no change is suggested. For uninsured or out-of-pocket patients, compounded semaglutide is made with the drug in Ozempic but is not the same product, and FLOW tested Ozempic, not compounded versions. Dose also matters: FLOW used semaglutide 1.0 mg weekly. Some compounded programs default to titrations targeting weight loss endpoints (2.4 mg-equivalent) rather than renoprotection endpoints. Patients with CKD-directed treatment goals should discuss target dose with the prescriber.

Monitoring on therapy

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.